Defining language disorders in children and adolescents with Noonan Syndrome.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
04 2020
Historique:
received: 26 07 2019
revised: 08 11 2019
accepted: 13 11 2019
pubmed: 15 2 2020
medline: 7 4 2021
entrez: 15 2 2020
Statut: ppublish

Résumé

Noonan Syndrome is a developmental disorder characterized by a distinctive phenotype including facial dysmorphism, webbed neck, short stature, heart defects, and variable cognitive deficits as major features. Over the years, neuropsychological and behavioral studies explored alteration of cognitive functioning and related domains, such as learning, memory, and attention. To our knowledge, however, data concerning the language profile in this disorder is scarce. The aim of the present study was to detect specific language functioning combining nonverbal intelligence quotient and language abilities and to pinpoint strengths and weaknesses in the language domains. The language profile of 37 Italian participants with molecularly confirmed diagnosis of Noonan Syndrome was evaluated using specific tools to assess vocabulary and grammar comprehension and production, as well as phonological development. We observed that 78% of affected individuals exhibited language impairment. Within language domains, the strong area was lexical production and grammar production was the weak area. Almost half the participants manifested a similar trend of specific language impairment. Nonverbal intelligence quotient only correlated with grammar comprehension. Our study expands present knowledge about the language profile in NS, and provides data that could enable more effective patient management and appropriate intervention.

Sections du résumé

BACKGROUND
Noonan Syndrome is a developmental disorder characterized by a distinctive phenotype including facial dysmorphism, webbed neck, short stature, heart defects, and variable cognitive deficits as major features. Over the years, neuropsychological and behavioral studies explored alteration of cognitive functioning and related domains, such as learning, memory, and attention. To our knowledge, however, data concerning the language profile in this disorder is scarce. The aim of the present study was to detect specific language functioning combining nonverbal intelligence quotient and language abilities and to pinpoint strengths and weaknesses in the language domains.
METHODS
The language profile of 37 Italian participants with molecularly confirmed diagnosis of Noonan Syndrome was evaluated using specific tools to assess vocabulary and grammar comprehension and production, as well as phonological development.
RESULTS
We observed that 78% of affected individuals exhibited language impairment. Within language domains, the strong area was lexical production and grammar production was the weak area. Almost half the participants manifested a similar trend of specific language impairment. Nonverbal intelligence quotient only correlated with grammar comprehension.
CONCLUSION
Our study expands present knowledge about the language profile in NS, and provides data that could enable more effective patient management and appropriate intervention.

Identifiants

pubmed: 32059087
doi: 10.1002/mgg3.1069
pmc: PMC7196479
doi:

Substances chimiques

PTPN11 protein, human EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 11 EC 3.1.3.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1069

Informations de copyright

© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

Références

Clin Linguist Phon. 2016 Jun 27;:1-12
pubmed: 27348294
Behav Genet. 2011 May;41(3):423-9
pubmed: 21274610
J Med Genet. 2015 Nov;52(11):719-29
pubmed: 26139234
N Engl J Med. 1963 Jul 11;269:70-4
pubmed: 13938861
J Speech Hear Disord. 1979 Nov;44(4):494-503
pubmed: 513672
Am J Med Genet A. 2014 Apr;164A(4):934-42
pubmed: 24458522
Am J Med Genet A. 2011 Oct;155A(10):2459-64
pubmed: 21910245
J Commun Disord. 1982 Sep;15(5):347-52
pubmed: 7130439
Nat Genet. 2007 Jan;39(1):70-4
pubmed: 17143285
Ann N Y Acad Sci. 2010 Dec;1214:99-121
pubmed: 20958325
Am J Dis Child. 1979 Aug;133(8):846-50
pubmed: 463839
Horm Res. 2009 Dec;72 Suppl 2:15-23
pubmed: 20029232
Am J Med Genet A. 2013 Sep;161A(9):2250-7
pubmed: 23918208
J Speech Lang Hear Res. 2010 Aug;53(4):917-32
pubmed: 20543023
Best Pract Res Clin Endocrinol Metab. 2011 Feb;25(1):161-79
pubmed: 21396583
Am J Med Genet. 1985 Jul;21(3):493-506
pubmed: 3895929
Arch Clin Neuropsychol. 2017 Aug 1;32(5):574-584
pubmed: 28419177
Nat Genet. 2007 Aug;39(8):1007-12
pubmed: 17603483
Nat Genet. 2007 Jan;39(1):75-9
pubmed: 17143282
J Child Lang. 2014 Jan;41(1):111-31
pubmed: 23286320
BMJ. 2000 Oct 14;321(7266):923-6
pubmed: 11030677
Neuropsychologia. 2002;40(13):2461-70
pubmed: 12417473
Dev Med Child Neurol. 2015 Apr;57(4):385-92
pubmed: 25366258
Nat Genet. 2001 Dec;29(4):465-8
pubmed: 11704759
Open Nurs J. 2013 May 14;7:82-8
pubmed: 23878620
Arch Dis Child. 1999 Jul;81(1):28-31
pubmed: 10373129
J Speech Lang Hear Res. 1997 Dec;40(6):1245-60
pubmed: 9430746
J Speech Lang Hear Res. 2004 Aug;47(4):924-43
pubmed: 15324296
Neuropsychologia. 2000;38(5):634-44
pubmed: 10689040
Neuropsychology. 2008 Jan;22(1):27-35
pubmed: 18211153
Neuropediatrics. 2008 Dec;39(6):335-40
pubmed: 19568997
Am J Ment Retard. 2003 May;108(3):149-60
pubmed: 12691594
Am J Med Genet. 1996 Dec 11;66(2):235-6
pubmed: 8958337
Eur J Paediatr Neurol. 2018 Jan;22(1):170-177
pubmed: 29037749
Am J Hum Genet. 2013 Jul 11;93(1):173-80
pubmed: 23791108
Genes Brain Behav. 2012 Oct;11(7):785-93
pubmed: 22783933
Mol Genet Genomic Med. 2020 Apr;8(4):e1069
pubmed: 32059087
Pediatrics. 2010 Oct;126(4):746-59
pubmed: 20876176
Int J Lang Commun Disord. 2007 Mar-Apr;42(2):187-208
pubmed: 17365093

Auteurs

Giulia Lazzaro (G)

Department of Neuroscience, Child and Adolescent Psychiatric Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Department of Human Science, LUMSA University of Rome, Rome, Italy.

Cristina Caciolo (C)

Department of Neuroscience, Child and Adolescent Psychiatric Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Deny Menghini (D)

Department of Neuroscience, Child and Adolescent Psychiatric Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Francesca Cumbo (F)

Department of Neuroscience, Child and Adolescent Psychiatric Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Maria C Digilio (MC)

Department of Medical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Rossella Capolino (R)

Department of Medical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Giuseppe Zampino (G)

Center for Rare Disease and Congenital Defects, Fondazione Policlinico Universitario A. Gemelli, Catholic University, Rome, Italy.

Marco Tartaglia (M)

Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Stefano Vicari (S)

Department of Neuroscience, Child and Adolescent Psychiatric Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Institute of Psychiatry, Fondazione Policlinico Universitario A. Gemelli, Catholic University, Rome, Italy.

Paolo Alfieri (P)

Department of Neuroscience, Child and Adolescent Psychiatric Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH